Child obesity drugs surge in Sweden, prescriptions more than double, regions absorb rising cost

• SVT reports that use of obesity drugs among children more than doubled in January-April versus the same period last year.
• The newer medicines are changing pediatric obesity treatment and moving drug therapy earlier into the system.
• The expansion raises questions about regional budgets, family access and how much treatment still relies on diet, exercise and follow-up care.
• Swedish practice now invites comparison with neighboring Nordic countries, where access rules and uptake differ.

Prescriptions of obesity drugs for Swedish children more than doubled in the first four months of 2025 compared with the same period last year, according to SVT Nyheter, which reports that the newer medicines have redrawn treatment options in pediatric care. The shift is not a marginal one: drugs once reserved for a narrow group are moving into ordinary regional healthcare for children with overweight and obesity.

SVT cites pediatrician Annika Janson saying the new medicines have "redrawn the playing field." That phrasing captures what the numbers show. Once a treatment category expands this quickly in a tax-funded system, the question is no longer whether the drugs exist but how broadly they will be used, who will qualify, and which part of the bill lands with families rather than the regions. In Sweden's decentralized healthcare model, that also means access can depend on where a child lives, how aggressively a clinic prescribes, and whether local budgets can absorb medicines that are far more expensive than advice on diet and exercise.

The medical case is clear enough for some children: obesity in adolescence can lead to diabetes, cardiovascular disease and years of treatment later on. But the speed of the increase gives the policy question its edge. If drug treatment is added on top of lifestyle interventions, clinics need more follow-up, more specialist staff and longer monitoring. If it starts to replace those interventions, the state is backing a pharmaceutical route for children before long-run evidence is fully built out. For adults, the market has already moved quickly. Pediatric use brings a different calculation, because treatment may begin earlier and continue for longer.

That leaves two filters in place: price and eligibility. Some obesity drugs are subsidized only under certain conditions, and reimbursement rules do not erase the practical barriers of referrals, specialist assessments and repeated visits. A family with time, transport and the ability to navigate the system has better odds than one without. The same welfare state now trying to contain childhood obesity is also deciding how much of that burden should be managed with injections, how much with counseling, and how much variation between regions is acceptable.

Comparison with Denmark, Norway and Finland matters because the Nordic countries tend to face the same public-health pressures while funding care through similar tax-based systems. If Sweden is moving faster, that suggests either looser prescribing, stronger clinical enthusiasm or faster acceptance of the budget impact. If its neighbors are moving at the same pace, then pediatric obesity drugs are becoming a standard welfare-state expense across the region rather than an exceptional treatment.

For now, the concrete fact is simple: in four months, the number of Swedish children receiving obesity medicine has more than doubled. The increase arrived before any Nordic consensus on how much childhood obesity treatment should cost, or how long a child may be expected to stay on the drug.

Källor: SVT Nyheter